<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00404534</url>
  </required_header>
  <id_info>
    <org_study_id>05-422</org_study_id>
    <nct_id>NCT00404534</nct_id>
  </id_info>
  <brief_title>Helicobacter Eradication Relief of Dyspeptic Symptoms</brief_title>
  <acronym>HEROES-12</acronym>
  <official_title>Dyspeptic Symptoms Evolution After Eradication of Helicobacter Pylori in Patients With Different Endoscopic Findings: a Randomized Double-blind Placebo-controlled Clinical Trial With 12 Months of Follow-up</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital de Clinicas de Porto Alegre</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Aché Laboratórios Farmacêuticos Ltda</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Hospital de Clinicas de Porto Alegre</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A double-blind clinical trial investigating if a sub-group of functional dyspeptic patients
      without any use of NSAID or gastric erosions could have a better evolution of their dyspeptic
      symptoms after Helicobacter eradication than the placebo control group
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Objective: investigate if a sub-group of functional dyspeptic patients without any use of
      NSAID or gastric erosions could have a better evolution of their dyspeptic symptoms after
      Helicobacter eradication than the placebo control group

      Design: A randomized double-blind placebo controlled clinical trial

      Inclusion Criteria: Patients with more than 18 years, Functional dyspepsia accordingly Rome
      III criteria, Helicobacter pylori infection by two diagnostic tests

      Exclusion Criteria: No concordance with informed consent; Pregnant woman or breast feeding or
      no trust anticonceptional method; Structural gastrointestinal abnormalities except gastritis,
      duodenitis or hiatal hernia; Previous treatment for Helicobacter pylori infection; Previous
      surgery on esophagus, stomach or duodenum; Hypersensitivity to the drugs in study; Proton
      pump inhibitor use in the previous 15 days; H2-antagonists use in the previous 07 days;
      Antibiotics use in the previous 30 days; Patients unable to answer the study questionnaires;
      Alcohol abuse; Drug use; Serious comorbidities; Biliary colic; Irritable bowel syndrome;
      Gastroesophageal Reflux Disease

      Interventions: amoxicillin, clarythromycin, omeprazole for 10 days

      Control: Placebo

      Outcomes:

      Primary: Proportion of patients with 50% reduction of baseline symptoms score measured by the
      validated Porto Alegre Dyspeptic Symptoms Questionnaire Secondary: Proportion of patients
      with 100% reduction of baseline symptoms score measured by the validated Porto Alegre
      Dyspeptic Symptoms Questionnaire; Need of rescue medication; Median difference of score
      between groups; Mean SF-36 scores evolution between groups; Lost of productivity measured by
      WPAI between groups

      Visits: screening, baseline, 4, 8, 12 months

      Endoscopic evaluation: screening, 12 months

      Helicobacter detection methods: urease, histology (3 pathologists) performed at screening and
      12 months
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2006</start_date>
  <completion_date type="Actual">June 2009</completion_date>
  <primary_completion_date type="Actual">June 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients with 50% reduction of baseline symptoms score measured by the validated Porto Alegre Dyspeptic Symptoms Questionnaire</measure>
    <time_frame>the last visit among the antecipated visits (4, 8 and 12 months)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with 100% reduction of baseline symptoms score measured by the validated Porto Alegre Dyspeptic Symptoms Questionnaire</measure>
    <time_frame>the last visit among the antecipated visits (4, 8 and 12 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Need of rescue medication</measure>
    <time_frame>4, 8 and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median difference of score between groups</measure>
    <time_frame>the last visit among the antecipated visits (4, 8 and 12 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean SF-36 scores evolution between groups</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lost of productivity measured by WPAI between groups</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>4 , 8 and 12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">407</enrollment>
  <condition>Functional Dyspepsia</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Amoxicillin 1000 mg BID, clarythromycin 500 mg BID and Omeprazole 20 mg BID for ten days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo of Amoxicillin 1000 mg BID, placebo of clarythromycin 500 mg BID and Omeprazole 20 mg BID for ten days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amoxicillin, Clarythromycin, Omeprazole for ten days</intervention_name>
    <description>Amoxicillin 1000 mg BID, clarythromycin 500 mg BID for ten days in the experimental group and placebo of Amoxicillin 1000 mg BID and placebo of clarythromycin 500 mg BID in the placebo comparator. Both groups receive omeprazole 20 mg bid for 10 days.</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with more than 18 years

          -  Functional dyspepsia accordingly Rome III criteria

          -  Helicobacter pylori infection by two diagnostic tests

        Exclusion Criteria:

          -  No concordance with informed consent

          -  Pregnant woman or breast feeding or no trust anticonceptional method

          -  Structural gastrointestinal abnormalities except gastritis, duodenitis or hiatal
             hernia

          -  Previous treatment for Helicobacter pylori infection

          -  Previous surgery on esophagus, stomach or duodenum

          -  Hypersensitivity to the drugs in study

          -  Proton pump inhibitor use in the previous 15 days

          -  H2-antagonists use in the previous 07 days

          -  Antibiotics use in the previous 30 days

          -  Patients unable to answer the study questionnaires

          -  Alcohol abuse

          -  Drug use

          -  Serious comorbidities

          -  Biliary colic

          -  Irritable bowel syndrome

          -  Gastroesophageal Reflux Disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Luiz E Mazzoleni, MD, MsC, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital de Clinicas de Porto Alegre, Universidade Federal do Rio Grande do Sul</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Carlos F Francesconi, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Hospital de Clinicas de Porto Alegre, Universidade Federal do Rio Grande do Sul</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Guilherme B Sander, MD, MsC</last_name>
    <role>Study Chair</role>
    <affiliation>Hospital de Clinicas de Porto Alegre, Universidade Federal do Rio Grande do Sul</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital de Clinicas de Porto Alegre</name>
      <address>
        <city>Porto Alegre</city>
        <state>Rio Grande Do Sul</state>
        <zip>90035-903</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <link>
    <url>http://www.hcpa.ufrgs.br</url>
    <description>Official Homepage of Site that is Conducting the Study</description>
  </link>
  <reference>
    <citation>Mazzoleni LE, Sander GB, Ott EA, Barros SG, Francesconi CF, Polanczyk CA, Wortmann AC, Theil AL, Fritscher LG, Rivero LF, Cartell A, Edelweiss MI, Uchôa DM, Prolla JC. Clinical outcomes of eradication of Helicobacter pylori in nonulcer dyspepsia in a population with a high prevalence of infection: results of a 12-month randomized, double blind, placebo-controlled study. Dig Dis Sci. 2006 Jan;51(1):89-98.</citation>
    <PMID>16416218</PMID>
  </reference>
  <reference>
    <citation>Ott EA, Mazzoleni LE, Edelweiss MI, Sander GB, Wortmann AC, Theil AL, Somm G, Cartell A, Rivero LF, Uchôa DM, Francesconi CF, Prolla JC. Helicobacter pylori eradication does not cause reflux oesophagitis in functional dyspeptic patients: a randomized, investigator-blinded, placebo-controlled trial. Aliment Pharmacol Ther. 2005 May 15;21(10):1231-9.</citation>
    <PMID>15882244</PMID>
  </reference>
  <reference>
    <citation>Sander GB, Mazzoleni LE, Francesconi CF, Wortmann AC, Ott EA, Theil A, Da Cruz PV, Da Silva AC, Oliveira L, Beheregaray S, Matioti S, Somm G, Goldim JR. Development and validation of a cross-cultural questionnaire to evaluate nonulcer dyspepsia: the Porto Alegre Dyspeptic Symptoms Questionnaire (PADYQ). Dig Dis Sci. 2004 Nov-Dec;49(11-12):1822-9.</citation>
    <PMID>15628711</PMID>
  </reference>
  <verification_date>March 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 27, 2006</study_first_submitted>
  <study_first_submitted_qc>November 27, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 28, 2006</study_first_posted>
  <last_update_submitted>February 27, 2018</last_update_submitted>
  <last_update_submitted_qc>February 27, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 1, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>functional dyspepsia</keyword>
  <keyword>Helicobacter pylori</keyword>
  <keyword>Anti-Inflammatory Agents, Non-Steroidal</keyword>
  <keyword>Gastritis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dyspepsia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amoxicillin</mesh_term>
    <mesh_term>Clarithromycin</mesh_term>
    <mesh_term>Omeprazole</mesh_term>
    <mesh_term>Anti-Inflammatory Agents, Non-Steroidal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

